A detailed history of Compagnie Lombard Odier S Cm A transactions in Incyte Corp stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 120 shares of INCY stock, worth $12,498. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120
Previous 1,120 89.29%
Holding current value
$12,498
Previous $94,000 87.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 16, 2026

SELL
$83.8 - $108.26 $83,800 - $108,260
-1,000 Reduced 89.29%
120 $12,000
Q3 2025

Nov 06, 2025

SELL
$67.27 - $86.96 $1.41 Million - $1.83 Million
-21,030 Reduced 94.94%
1,120 $94,000
Q2 2025

Jul 15, 2025

BUY
$55.17 - $71.22 $167,165 - $215,796
3,030 Added 15.85%
22,150 $1.51 Million
Q1 2025

Apr 16, 2025

BUY
$60.0 - $75.26 $1.14 Million - $1.43 Million
19,000 Added 15833.33%
19,120 $1.16 Million
Q2 2024

Jul 18, 2024

SELL
$51.18 - $63.75 $26,613 - $33,150
-520 Reduced 81.25%
120 $7,000
Q1 2023

May 01, 2023

SELL
$70.23 - $86.01 $67,842 - $83,085
-966 Reduced 60.15%
640 $46,000
Q4 2022

Feb 13, 2023

BUY
$67.18 - $84.11 $64,895 - $81,250
966 Added 150.94%
1,606 $130,000
Q1 2021

Apr 23, 2021

BUY
$76.02 - $100.5 $29,647 - $39,195
390 Added 156.0%
640 $52,000
Q3 2018

Nov 13, 2018

SELL
$61.75 - $74.23 $185,250 - $222,690
-3,000 Reduced 92.31%
250 $17,000
Q2 2018

Aug 10, 2018

BUY
$60.85 - $83.98 $60,850 - $83,980
1,000 Added 44.44%
3,250 $218,000
Q4 2017

Feb 13, 2018

SELL
$93.56 - $116.6 $74,848 - $93,280
-800 Reduced 26.23%
2,250 $213,000
Q3 2017

Nov 14, 2017

SELL
$109.15 - $138.27 $5,457 - $6,913
-50 Reduced 1.61%
3,050 $355,000
Q2 2017

Aug 14, 2017

BUY
N/A
3,100
3,100 $390,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $23.2B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Compagnie Lombard Odier S Cm A Portfolio

Follow Compagnie Lombard Odier S Cm A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

News

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.